What is Hidradenitis Suppurativa?

Hidradenitis Suppurativa is a chronic and often painful inflammatory skin disease.

What you should know about Hidradenitis Suppurativa

Hidradenitis Suppurativa (HS), is a chronic skin condition characterised by inflamed areas typically located around the armpits and groin. These inflamed areas often include painful lesions, nodules and boils, and usually occur where certain sweat glands (known as apocrine glands) are located, as well as under the breasts, on the buttocks and in the inner thighs, where skin rubs together. Hidradenitis Suppurativa is not an infectious or contagious disease.

What causes Hidradenitis Suppurativa?

Though it affects the skin, Hidradenitis Suppurativa is an inflammatory disorder, which means the condition is brought on by irregularities in the body’s own immune system. Hidradenitis Suppurativa can occur at any age, but the condition most commonly develops in adults in their early 20s, with declining rates after the age of 50.

Visit HS-Online.co.nz for more information

References:

Humira Approved Consumer Medical Information.
Mayo Health Clinic. Hidradenitis Suppurativa. Available at: https://www.mayoclinic.org/diseases-conditions/hidradenitis-suppurativa/home/ovc-20200012. Accessed March 28, 2019.
Jemec G. Hidradenitis Suppurativa. N Engl J Med. 2012; 366:158-64.
Zouboulis CC, Tsatsou F. Disorders of the apocrine sweat glands. In: Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, Wolff K. Fitzpatrick’s Dermatology in General Medicine. 8th ed. New York, Chicago: McGraw Hill; 2012. p947-959.

This site is intended for a New Zealand audience.

Important information about HUMIRA. HUMIRA is a prescription medicine containing adalimumab. HUMIRA is available as a single use pre-filled syringe or single-use pre-filled pen and may contain 20mg, 40mg or 80mg adalimumab. It is used in the treatment of patients with rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, enthesitis-related arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, psoriasis, ulcerative colitis, Crohn’s disease, non-infectious uveitis, and hidradenitis suppurativa. HUMIRA is only used in patients of a specific age group, in diseases of certain severity (e.g. moderate to severe), and/or after some other treatments have been tried (e.g. conventional therapy).

HUMIRA has risks and benefits. Refer to the Safety Information contained on this website for further details. If you have any questions about using HUMIRA, ask your healthcare professional and refer to the Consumer Medicine Information (CMI) available here: HUMIRA PEN CMI or HUMIRA Pre-filled Syringe CMI or by calling freephone 0800 900 030. Ask your doctor if HUMIRA is right for you. Use strictly as directed. If symptoms continue, or you have side effects, see your doctor, pharmacist or healthcare professional.

HUMIRA is a funded prescription medicine under special authorial criteria – for certain indications and patients only. Your doctor can inform you if you are eligible to receive funding. Normal pharmacy and doctor's charge will apply.

AbbVie is the company that brings you HUMIRA (adalimumab). For more information about AbbVie, visit www.AbbVie.co.nz | HUMIRA Data Sheet

AbbVie Limited, 6th floor, 156-158 Victoria street, Wellington, 6011, New Zealand 0800 900 030. HUMIRA and Destination You are registered trademarks of AbbVie Biotechnology Ltd.